Literature DB >> 31172114

Future Direction of Emergency Medicine Research; Can We Overcome the Difficulties and Fill in Knowledge Gaps?

Zinat Nadia Hatmi1,2.   

Abstract

Entities:  

Year:  2019        PMID: 31172114      PMCID: PMC6548078          DOI: 10.22114/AJEM.v3i1.120

Source DB:  PubMed          Journal:  Adv J Emerg Med        ISSN: 2588-400X


× No keyword cloud information.
Pace of medical research development heralded an escalation in recent years. Groundbreaking evidences have been provided for managing dyslipidemia in 2017. Beside statins, alternatives of Anti PCSK-9 monoclonal antibodies in human (1) and AT04A anti PCSK-9 vaccine (2) in mice have shown to significant decrease in total cholesterol level. Wonderful! Apart from this, dual pathway inhibition by using aspirin with very low dose Rivaroxaban has been shown to be more effective in mitigating ischemic event rate than aspirin alone in patients with stable coronary artery disease or peripheral artery disease (3). Furthermore, patients with atrial fibrillation undergo percutaneous coronary intervention will benefit more from double antithrombotic therapy than triple one (4, 5). Besides, a novel risk score of PRECISE-DAPT has determine the optimal duration of antiplatelet therapy in patients implanting coronary stents (6); and many other medical research advances which grabs our attention on 2018. In order to translate recent advances in medical research into clinical practice we need to design, conduct and apply high quality research in different medical subspecialties. The emergency medicine (EM) environment defined as overburdened with inability to afford more than a few minutes per patients. Where, time for research might be considered as a potential risk of interruption in clinical practice. EM is a broad field involving multiple disciplines and crosscutting themes with the unique features in research including urgency and location of the treatment. Art of research in EM comprises hybridization of clinical research, basic science and health services research. Accordingly, research priority setting should be put forwarded based on these three areas, examining existing gaps in EM knowledge, system design issues, educational predicament and disparities between diagnostic skills and clinical decisions (7-9). Where the most appropriate research questions arise? Definitely, it comes from critical thinking in patient care setting, regular reading habit, teaching, journal clubs, collaborations and society. To alleviate the issue of immense question and limited time in EM field which tangles decision makers mind we recommend to prioritize questions in line with; patients well- being, learners need, feasibility to answer, inquiries that most likely to recur in your practice and most interesting foreground research query. A research need has been defined as a gap in existing knowledge on practice, learner‚s education, patient values and societal demands. To examine the gaps in EM research knowledge we can provide research time and facilities, training new investigators, develop multicenter research networks, improve research coordination and involving funding agencies to make practical attempts for filling pre specified gaps (10, 11). In conclusion, since patient oriented outcome research will provide us with the most important endpoints for clinical policy making and patient care standard setting, I totally agree with the advocates of involving stakeholders including clinicians, society and patients in EM research process to mitigate the existence knowledge gaps for dedicating high quality EM care.
  11 in total

1.  Clinical research in emergency medicine: putting it together.

Authors:  A M T Good; P Driscoll
Journal:  Emerg Med J       Date:  2002-05       Impact factor: 2.740

2.  The emergency medicine research priority setting partnership.

Authors:  Jason E Smith; Richard Morley
Journal:  Emerg Med J       Date:  2015-09-29       Impact factor: 2.740

3.  Investing in emergency medicine to improve health care for all Americans: the role of the Agency for Healthcare Research and Quality.

Authors:  Ryan Mutter; Carolyn Clancy
Journal:  Ann Emerg Med       Date:  2013-07-18       Impact factor: 5.721

4.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Authors:  Stuart J Connolly; John W Eikelboom; Jackie Bosch; Gilles Dagenais; Leanne Dyal; Fernando Lanas; Kaj Metsarinne; Martin O'Donnell; Anthony L Dans; Jong-Won Ha; Alexandr N Parkhomenko; Alvaro A Avezum; Eva Lonn; Liu Lisheng; Christian Torp-Pedersen; Petr Widimsky; Aldo P Maggioni; Camilo Felix; Katalin Keltai; Masatsugu Hori; Khalid Yusoff; Tomasz J Guzik; Deepak L Bhatt; Kelley R H Branch; Nancy Cook Bruns; Scott D Berkowitz; Sonia S Anand; John D Varigos; Keith A A Fox; Salim Yusuf
Journal:  Lancet       Date:  2017-11-10       Impact factor: 79.321

5.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

Review 6.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.

Authors:  Francesco Costa; David van Klaveren; Stefan James; Dik Heg; Lorenz Räber; Fausto Feres; Thomas Pilgrim; Myeong-Ki Hong; Hyo-Soo Kim; Antonio Colombo; Philippe Gabriel Steg; Thomas Zanchin; Tullio Palmerini; Lars Wallentin; Deepak L Bhatt; Gregg W Stone; Stephan Windecker; Ewout W Steyerberg; Marco Valgimigli
Journal:  Lancet       Date:  2017-03-11       Impact factor: 79.321

7.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; Ulf Landmesser; Lawrence A Leiter; David Kallend; Robert Dufour; Mahir Karakas; Tim Hall; Roland P T Troquay; Traci Turner; Frank L J Visseren; Peter Wijngaard; R Scott Wright; John J P Kastelein
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

8.  An Emergency Medicine Research Priority Setting Partnership to establish the top 10 research priorities in emergency medicine.

Authors:  Jason Smith; Liza Keating; Lynsey Flowerdew; Rachel O'Brien; Sam McIntyre; Richard Morley; Simon Carley
Journal:  Emerg Med J       Date:  2017-05-04       Impact factor: 2.740

9.  Improving emergency department flow through Rapid Medical Evaluation unit.

Authors:  Lucas Chartier; Timothy Josephson; Kathy Bates; Meredith Kuipers
Journal:  BMJ Qual Improv Rep       Date:  2015-12-01

10.  The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.

Authors:  Christine Landlinger; Marianne G Pouwer; Claudia Juno; José W A van der Hoorn; Elsbet J Pieterman; J Wouter Jukema; Guenther Staffler; Hans M G Princen; Gergana Galabova
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.